Immunome Research
Open Access

Overview on Activation Immunotherapies

Michael D. Green^{* *}Correspondence: Michael D. Green, Department of Immunology and Immunotherapy, University of Michigan Cancer Center, Michigan, USA, Email:

Author info »

Editorial Note

Immunotherapy is the process of stimulating or inhibiting the immune system in order to cure illness. Activation immunotherapies are immunotherapies that are meant to generate or increase an immune response.

Chemotherapy, surgery, and radiation were formerly the mainstays of cancer treatment, with the goal of killing or eliminating cancer cells and tumours. These therapies can be highly successful, and they are still utilised in many situations. Cancer immunotherapy aims to boost the immune system's ability to fight tumours. A number of techniques are now in use or are being researched and tested. Cell-based immunotherapy has been shown to improve survival and disease-free time in randomised controlled experiments in various malignancies, and its efficacy is increased by 20–30 percent when coupled with traditional treatment approaches.

The BCG vaccination, which was originally developed to prevent TB but subsequently shown to be beneficial in the treatment of bladder cancer, is one of the earliest types of cancer immunotherapy. Both local and systemic immune responses are induced by BCG treatment. The methods by which BCG immunotherapy induces tumour immunity have been extensively researched, yet they remain a mystery. The tumour cells that express the antigen are then destroyed by the cells. To cure warts, injectable immunotherapy utilises mumps, candida, the HPV vaccination, or trichophytin antigen injections. Intralesional or intratumoural immunotherapies are additional terms for injection immunotherapy.

Antigen-presenting cells of the mammalian immune system are known as Dendritic cells (DCs). Their major job is to digest antigen material and present it to immune system T cells on the cell surface. They serve as conduits for information between the innate and adaptive immune systems. DCs can be induced to initiate a cytotoxic response to an antigen. Dendritic cells, a kind of antigen-presenting cell, are taken from the immunotherapy patient. These cells are then either pulsed with an antigen or tumour lysate, or transfected with a viral vector, causing the antigen to be shown. These activated cells present the antigen to the effector lymphocytes after being transfused into the individual. This triggers a cytotoxic response against antigenexpressing tumour cells (against which the adaptive response has now been primed). One example of this method is the cancer vaccination Sipuleucel-T.

Antigen loading on in vitro-generated DCs from monocytes or CD34+ cells, activation with various TLR ligands and cytokine combinations, and injection back into patients are the current techniques for DC-based vaccination. Administering particular cytokines and targeting DCs with antibodies to C-type lectin receptors or agonistic antibodies conjugated with the antigen of interest are two in vivo targeting techniques. Future strategies might focus on DC subsets with highly expressed C-type lectin receptors or chemokine receptors. To enhance clinical results, another option is to use genetically modified DCs generated from induced pluripotent stem cells, as well as neoantigenloaded DCs. These treatments have revolutionised cancer immunotherapy by demonstrating an improvement in overall survival in metastatic melanoma, one of the most immunogenic human cancers, for the first time in many years of research, with an increasing number of patients benefiting long-term from these treatments.